FDA Clears Radiology AI Enterprise Imaging Platform from CARPL.ai
Offering access to over 110 AI applications, the enterprise imaging platform enables radiologists to test, deploy and monitor the use of AI technologies.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the CARPL.ai enterprise imaging artificial intelligence (AI) platform, a development that may help streamline the adoption of AI into radiology workflows.
CARPL.ai noted the platform allows radiologists access to over 110 AI applications from over 50 vendors with a single user interface. The platform facilitates worklist triage, segmentation, clinical audits, and auto-populated reports, according to the company.
Noting the adaptable capability of the platform for on-site or cloud-based hosting, CARPL.ai emphasized the potential for rapid scaling with no incremental costs for piloting of AI applications.
Vijay Rao, M.D., FACR, a senior vice president of enterprise radiology and imaging ay Jefferson Health in Philadelphia, added that the FDA clearance of the CARPL.ai platform allows for PACS integration of FDA-cleared AI applications that don’t have separate FDA-cleared viewers.
“This FDA clearance opens the door for widespread adoption of AI solutions through a platform approach which simplifies the process of selection, implementation, and procurement of AI by health systems,” noted Vidur Mahajan, the chief executive officer at CARPL.ai.
The Reading Room Podcast: Emerging Trends in the Radiology Workforce
February 11th 2022Richard Duszak, MD, and Mina Makary, MD, discuss a number of issues, ranging from demographic trends and NPRPs to physician burnout and medical student recruitment, that figure to impact the radiology workforce now and in the near future.
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.
